| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Androgen Antagonists | 75 | 2022 | 1411 | 8.180 |
Why?
|
| Prostatic Neoplasms | 161 | 2018 | 11080 | 8.150 |
Why?
|
| Gonadotropin-Releasing Hormone | 47 | 2015 | 1133 | 5.810 |
Why?
|
| Bone Neoplasms | 55 | 2019 | 2564 | 5.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 48 | 2017 | 1533 | 5.250 |
Why?
|
| Diphosphonates | 41 | 2016 | 625 | 4.670 |
Why?
|
| Bone Density Conservation Agents | 37 | 2016 | 791 | 4.480 |
Why?
|
| Leuprolide | 13 | 2015 | 311 | 2.930 |
Why?
|
| Orchiectomy | 29 | 2015 | 460 | 2.920 |
Why?
|
| Toremifene | 10 | 2013 | 26 | 2.860 |
Why?
|
| Imidazoles | 24 | 2016 | 1163 | 2.760 |
Why?
|
| Anilides | 13 | 2016 | 415 | 2.730 |
Why?
|
| Osteoporosis | 31 | 2012 | 1582 | 2.600 |
Why?
|
| Prostate-Specific Antigen | 36 | 2018 | 2462 | 2.000 |
Why?
|
| Phenylthiohydantoin | 5 | 2017 | 206 | 1.920 |
Why?
|
| RANK Ligand | 10 | 2013 | 320 | 1.710 |
Why?
|
| Bone Density | 28 | 2012 | 3490 | 1.440 |
Why?
|
| Prednisone | 15 | 2019 | 1563 | 1.420 |
Why?
|
| Antineoplastic Agents | 32 | 2022 | 13639 | 1.360 |
Why?
|
| Fractures, Bone | 19 | 2019 | 2040 | 1.280 |
Why?
|
| Neoplasms, Hormone-Dependent | 12 | 2014 | 409 | 1.250 |
Why?
|
| Thiohydantoins | 2 | 2018 | 19 | 1.140 |
Why?
|
| Osteoclasts | 9 | 2012 | 713 | 1.140 |
Why?
|
| Body Composition | 12 | 2014 | 2441 | 1.140 |
Why?
|
| Nitriles | 13 | 2017 | 982 | 1.100 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2016 | 123 | 1.070 |
Why?
|
| Goserelin | 5 | 2015 | 126 | 1.020 |
Why?
|
| Adenocarcinoma | 11 | 2014 | 6356 | 1.000 |
Why?
|
| Bone and Bones | 14 | 2014 | 2554 | 0.910 |
Why?
|
| Pyridines | 6 | 2016 | 2889 | 0.900 |
Why?
|
| Male | 196 | 2022 | 363585 | 0.860 |
Why?
|
| Tosyl Compounds | 7 | 2008 | 115 | 0.830 |
Why?
|
| Prostatectomy | 13 | 2016 | 1783 | 0.800 |
Why?
|
| Double-Blind Method | 27 | 2021 | 12433 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2022 | 11865 | 0.760 |
Why?
|
| Aged | 111 | 2021 | 171050 | 0.720 |
Why?
|
| Bone Diseases | 4 | 2010 | 411 | 0.700 |
Why?
|
| Aged, 80 and over | 58 | 2021 | 59459 | 0.690 |
Why?
|
| Castration | 4 | 2013 | 149 | 0.680 |
Why?
|
| Spinal Fractures | 3 | 2011 | 703 | 0.670 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 4885 | 0.660 |
Why?
|
| Radium | 3 | 2019 | 70 | 0.660 |
Why?
|
| Androgens | 12 | 2022 | 1278 | 0.650 |
Why?
|
| Cardiovascular Diseases | 19 | 2015 | 15648 | 0.650 |
Why?
|
| Bone Remodeling | 8 | 2016 | 577 | 0.640 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 6832 | 0.580 |
Why?
|
| Humans | 202 | 2022 | 765734 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 9 | 2011 | 9245 | 0.560 |
Why?
|
| Collagen Type I | 7 | 2016 | 616 | 0.560 |
Why?
|
| Diabetes Complications | 3 | 2013 | 1316 | 0.510 |
Why?
|
| Oligopeptides | 2 | 2011 | 1192 | 0.490 |
Why?
|
| Osteoblasts | 5 | 2013 | 1143 | 0.490 |
Why?
|
| Fractures, Spontaneous | 5 | 2015 | 230 | 0.480 |
Why?
|
| Pyrazoles | 2 | 2021 | 2031 | 0.480 |
Why?
|
| Diabetes Mellitus | 8 | 2014 | 5891 | 0.480 |
Why?
|
| Flutamide | 4 | 2015 | 95 | 0.470 |
Why?
|
| Neoplastic Cells, Circulating | 8 | 2016 | 949 | 0.470 |
Why?
|
| Middle Aged | 83 | 2021 | 222903 | 0.470 |
Why?
|
| Urogenital Neoplasms | 3 | 2012 | 129 | 0.460 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1171 | 0.440 |
Why?
|
| Digital Rectal Examination | 2 | 2012 | 42 | 0.420 |
Why?
|
| Myostatin | 1 | 2014 | 129 | 0.420 |
Why?
|
| Insulin Resistance | 9 | 2013 | 3989 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2016 | 5693 | 0.400 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 287 | 0.390 |
Why?
|
| Disease Progression | 24 | 2017 | 13614 | 0.390 |
Why?
|
| Testosterone | 10 | 2017 | 2495 | 0.390 |
Why?
|
| Alkaline Phosphatase | 7 | 2014 | 855 | 0.380 |
Why?
|
| Prostate | 5 | 2015 | 1752 | 0.380 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 1945 | 0.370 |
Why?
|
| Benzamides | 5 | 2017 | 1376 | 0.360 |
Why?
|
| Treatment Outcome | 39 | 2017 | 65180 | 0.360 |
Why?
|
| Androstenes | 5 | 2015 | 178 | 0.350 |
Why?
|
| Kallikreins | 3 | 2017 | 220 | 0.350 |
Why?
|
| Sarcopenia | 2 | 2013 | 378 | 0.350 |
Why?
|
| Thiazolidinediones | 2 | 2004 | 459 | 0.340 |
Why?
|
| Peptides | 8 | 2016 | 4331 | 0.340 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1622 | 0.330 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2006 | 134 | 0.330 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2014 | 407 | 0.330 |
Why?
|
| Absorptiometry, Photon | 5 | 2012 | 1707 | 0.330 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 687 | 0.330 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 658 | 0.320 |
Why?
|
| Taxoids | 8 | 2016 | 665 | 0.320 |
Why?
|
| Quality of Life | 6 | 2021 | 13462 | 0.310 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 852 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 561 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2016 | 9368 | 0.300 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 108 | 0.300 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 279 | 0.300 |
Why?
|
| Body Mass Index | 6 | 2014 | 13044 | 0.300 |
Why?
|
| Pyrrolidines | 2 | 2006 | 337 | 0.280 |
Why?
|
| Veterans | 2 | 2012 | 2663 | 0.280 |
Why?
|
| Obesity | 6 | 2013 | 13079 | 0.270 |
Why?
|
| Androstadienes | 3 | 2013 | 347 | 0.270 |
Why?
|
| Clinical Trials as Topic | 12 | 2013 | 8038 | 0.270 |
Why?
|
| Steroids | 2 | 2012 | 931 | 0.260 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 682 | 0.250 |
Why?
|
| Osteoblastoma | 1 | 2005 | 24 | 0.250 |
Why?
|
| Adipokines | 1 | 2008 | 308 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3737 | 0.250 |
Why?
|
| Incidence | 15 | 2015 | 21478 | 0.250 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1789 | 0.250 |
Why?
|
| Estramustine | 2 | 2005 | 35 | 0.240 |
Why?
|
| Metabolome | 1 | 2012 | 1005 | 0.240 |
Why?
|
| Survival Rate | 14 | 2016 | 12787 | 0.240 |
Why?
|
| Time Factors | 19 | 2017 | 40066 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6499 | 0.240 |
Why?
|
| Proportional Hazards Models | 13 | 2015 | 12509 | 0.230 |
Why?
|
| Placebos | 5 | 2014 | 1659 | 0.230 |
Why?
|
| Spinal Cord | 1 | 2012 | 1783 | 0.230 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 318 | 0.230 |
Why?
|
| Watchful Waiting | 3 | 2015 | 493 | 0.220 |
Why?
|
| Fatigue | 2 | 2008 | 1550 | 0.210 |
Why?
|
| Risk Factors | 22 | 2017 | 74831 | 0.200 |
Why?
|
| Signal Transduction | 4 | 2017 | 23589 | 0.200 |
Why?
|
| Lipids | 3 | 2008 | 3315 | 0.200 |
Why?
|
| Salvage Therapy | 3 | 2016 | 1272 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2012 | 12238 | 0.200 |
Why?
|
| Exercise Therapy | 1 | 2009 | 937 | 0.190 |
Why?
|
| Chromans | 1 | 2002 | 116 | 0.190 |
Why?
|
| Administration, Oral | 4 | 2017 | 4015 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1731 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 878 | 0.190 |
Why?
|
| Adipose Tissue | 4 | 2014 | 3313 | 0.190 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 11201 | 0.190 |
Why?
|
| Prospective Studies | 17 | 2014 | 54795 | 0.180 |
Why?
|
| Endocrinology | 1 | 2007 | 442 | 0.180 |
Why?
|
| Follow-Up Studies | 15 | 2017 | 39180 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 616 | 0.180 |
Why?
|
| Indazoles | 1 | 2022 | 303 | 0.170 |
Why?
|
| SEER Program | 5 | 2014 | 1444 | 0.170 |
Why?
|
| Adult | 31 | 2022 | 222974 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2004 | 3169 | 0.170 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 4850 | 0.160 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2014 | 99 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4961 | 0.160 |
Why?
|
| Vinblastine | 1 | 2000 | 483 | 0.160 |
Why?
|
| Radiotherapy | 4 | 2011 | 1494 | 0.160 |
Why?
|
| Cholesterol | 1 | 2008 | 2898 | 0.160 |
Why?
|
| Kidney Neoplasms | 4 | 2012 | 4262 | 0.160 |
Why?
|
| Clodronic Acid | 2 | 2012 | 60 | 0.160 |
Why?
|
| Risk Assessment | 17 | 2012 | 24279 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 518 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3537 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 6307 | 0.150 |
Why?
|
| Myocardial Infarction | 4 | 2012 | 11504 | 0.150 |
Why?
|
| Complementary Therapies | 2 | 2004 | 487 | 0.150 |
Why?
|
| Bone Resorption | 4 | 2010 | 717 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10428 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3236 | 0.150 |
Why?
|
| Prednisolone | 1 | 2019 | 324 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2002 | 794 | 0.140 |
Why?
|
| Receptors, Androgen | 2 | 2015 | 1087 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7424 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2012 | 1567 | 0.140 |
Why?
|
| Odds Ratio | 5 | 2015 | 9647 | 0.140 |
Why?
|
| Prognosis | 12 | 2015 | 29899 | 0.140 |
Why?
|
| Triazoles | 1 | 2002 | 897 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2017 | 10385 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2006 | 1981 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2012 | 10069 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 12056 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5336 | 0.130 |
Why?
|
| Cohort Studies | 10 | 2016 | 41631 | 0.120 |
Why?
|
| Thiazoles | 1 | 2002 | 1529 | 0.120 |
Why?
|
| Body Weight | 2 | 2010 | 4624 | 0.120 |
Why?
|
| Radionuclide Imaging | 3 | 2014 | 1978 | 0.110 |
Why?
|
| Osteocalcin | 3 | 2008 | 271 | 0.110 |
Why?
|
| Gynecomastia | 1 | 2014 | 87 | 0.110 |
Why?
|
| Procollagen | 2 | 2011 | 189 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2004 | 12123 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3717 | 0.110 |
Why?
|
| Androstenols | 2 | 2010 | 25 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2006 | 2820 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 5388 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1663 | 0.110 |
Why?
|
| Carcinoma | 2 | 2016 | 2309 | 0.110 |
Why?
|
| Samarium | 1 | 2012 | 3 | 0.100 |
Why?
|
| Estradiol | 3 | 2007 | 1947 | 0.100 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2012 | 5 | 0.100 |
Why?
|
| Pyrroles | 3 | 2014 | 1119 | 0.100 |
Why?
|
| DNA Repair | 1 | 2022 | 2051 | 0.100 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 98 | 0.100 |
Why?
|
| Forecasting | 2 | 2016 | 2936 | 0.100 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2012 | 134 | 0.100 |
Why?
|
| United States | 15 | 2014 | 72898 | 0.100 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2007 | 558 | 0.100 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 75 | 0.100 |
Why?
|
| Retrospective Studies | 17 | 2017 | 81457 | 0.100 |
Why?
|
| Comorbidity | 3 | 2012 | 10567 | 0.100 |
Why?
|
| Acid Phosphatase | 1 | 2011 | 137 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3109 | 0.100 |
Why?
|
| Risk | 3 | 2014 | 9592 | 0.100 |
Why?
|
| Hot Flashes | 1 | 2014 | 330 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2015 | 722 | 0.090 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2004 | 142 | 0.090 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 123 | 0.090 |
Why?
|
| Femur | 2 | 2012 | 1310 | 0.090 |
Why?
|
| Indoles | 3 | 2014 | 1832 | 0.090 |
Why?
|
| Hip | 1 | 2012 | 249 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 869 | 0.090 |
Why?
|
| Algorithms | 2 | 2010 | 14061 | 0.090 |
Why?
|
| Calcium, Dietary | 2 | 2004 | 526 | 0.090 |
Why?
|
| Depression | 2 | 2008 | 8230 | 0.080 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 1325 | 0.080 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 398 | 0.080 |
Why?
|
| Haplotypes | 1 | 2016 | 2728 | 0.080 |
Why?
|
| Models, Biological | 2 | 2017 | 9441 | 0.080 |
Why?
|
| Breast Neoplasms | 8 | 2011 | 21053 | 0.080 |
Why?
|
| Leg | 1 | 2014 | 1080 | 0.080 |
Why?
|
| Hypogonadism | 2 | 2008 | 801 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1160 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2015 | 2132 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10730 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 1099 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 13448 | 0.070 |
Why?
|
| Fractures, Malunited | 1 | 2008 | 82 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2011 | 1688 | 0.070 |
Why?
|
| Pain | 3 | 2014 | 5074 | 0.070 |
Why?
|
| Hyperaldosteronism | 1 | 2010 | 252 | 0.070 |
Why?
|
| Kinetics | 2 | 2015 | 6272 | 0.070 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 1874 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2014 | 2600 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 2218 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2845 | 0.060 |
Why?
|
| Estrogens | 2 | 2003 | 1529 | 0.060 |
Why?
|
| DNA Damage | 1 | 2016 | 2461 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2008 | 245 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2010 | 796 | 0.060 |
Why?
|
| DNA, Antisense | 1 | 2005 | 44 | 0.060 |
Why?
|
| Neoplasms | 3 | 2009 | 22345 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2012 | 2653 | 0.060 |
Why?
|
| Coronary Disease | 2 | 2012 | 5911 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 2699 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 698 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2229 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2012 | 2423 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2007 | 752 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4809 | 0.060 |
Why?
|
| Spine | 1 | 2012 | 1129 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2016 | 2891 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 1377 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 363 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 84 | 0.060 |
Why?
|
| Diagnostic Imaging | 3 | 2014 | 3526 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 411 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 2010 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 324 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 1892 | 0.050 |
Why?
|
| Cross-Sectional Studies | 5 | 2008 | 26284 | 0.050 |
Why?
|
| Age Factors | 3 | 2016 | 18375 | 0.050 |
Why?
|
| Ureteral Neoplasms | 1 | 2004 | 106 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 15883 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2003 | 127 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2004 | 151 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2011 | 6319 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 1180 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 2882 | 0.050 |
Why?
|
| Female | 22 | 2016 | 395961 | 0.050 |
Why?
|
| Biopsy | 2 | 2011 | 6754 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2014 | 1528 | 0.050 |
Why?
|
| Edema | 1 | 2006 | 760 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1120 | 0.050 |
Why?
|
| Causality | 1 | 2008 | 1246 | 0.050 |
Why?
|
| Cell Separation | 1 | 2007 | 1718 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2009 | 1282 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 88781 | 0.050 |
Why?
|
| Multiple Myeloma | 3 | 2009 | 5195 | 0.050 |
Why?
|
| Syndrome | 1 | 2008 | 3268 | 0.050 |
Why?
|
| Serenoa | 1 | 2001 | 11 | 0.050 |
Why?
|
| Carboplatin | 1 | 2005 | 789 | 0.050 |
Why?
|
| Survivors | 2 | 2012 | 2374 | 0.050 |
Why?
|
| Alendronate | 1 | 2003 | 174 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2009 | 869 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 1811 | 0.050 |
Why?
|
| Flushing | 1 | 2001 | 52 | 0.050 |
Why?
|
| Neutrophils | 1 | 2014 | 3772 | 0.050 |
Why?
|
| Hypericum | 1 | 2001 | 58 | 0.050 |
Why?
|
| Anthropometry | 1 | 2006 | 1339 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2005 | 744 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2822 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2005 | 916 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2003 | 498 | 0.040 |
Why?
|
| Acupuncture | 1 | 2001 | 90 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1181 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 367 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1311 | 0.040 |
Why?
|
| Triglycerides | 1 | 2008 | 2441 | 0.040 |
Why?
|
| Animals | 6 | 2015 | 168731 | 0.040 |
Why?
|
| Weight Gain | 1 | 2010 | 2355 | 0.040 |
Why?
|
| Coronary Artery Disease | 2 | 2010 | 6545 | 0.040 |
Why?
|
| Rats | 2 | 2008 | 23704 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 2002 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2004 | 889 | 0.040 |
Why?
|
| Thalidomide | 1 | 2005 | 886 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 1775 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 7584 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1203 | 0.040 |
Why?
|
| Vitamin D | 1 | 2013 | 3272 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 250 | 0.040 |
Why?
|
| Pyrazines | 1 | 2005 | 1204 | 0.040 |
Why?
|
| Pelvic Bones | 1 | 2001 | 273 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5125 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 299 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1882 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 639 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2393 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2002 | 8732 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 14637 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14745 | 0.040 |
Why?
|
| Dyspnea | 1 | 2006 | 1352 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 967 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2005 | 4752 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2010 | 2339 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5302 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2017 | 1639 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 705 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2208 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8528 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3835 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3955 | 0.040 |
Why?
|
| Ketoconazole | 2 | 2010 | 93 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2001 | 498 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2012 | 2175 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 2001 | 515 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2002 | 866 | 0.030 |
Why?
|
| Erythropoietin | 1 | 2001 | 716 | 0.030 |
Why?
|
| Health Status | 1 | 2009 | 4081 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3850 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4472 | 0.030 |
Why?
|
| Collagen | 1 | 2004 | 2618 | 0.030 |
Why?
|
| Inflammation | 2 | 2014 | 10846 | 0.030 |
Why?
|
| Canada | 2 | 2013 | 2119 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 271 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15390 | 0.030 |
Why?
|
| Food-Drug Interactions | 1 | 2014 | 26 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 2864 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 23 | 0.030 |
Why?
|
| Densitometry | 2 | 2004 | 150 | 0.030 |
Why?
|
| Morbidity | 2 | 2010 | 1749 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 4858 | 0.030 |
Why?
|
| Boston | 1 | 2007 | 9337 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2108 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 386 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 597 | 0.030 |
Why?
|
| Cell Survival | 1 | 2003 | 5747 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2015 | 495 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2014 | 3559 | 0.030 |
Why?
|
| Michigan | 1 | 2014 | 328 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 2046 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2008 | 8533 | 0.020 |
Why?
|
| Disease Management | 1 | 2003 | 2534 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 380 | 0.020 |
Why?
|
| Radiography | 2 | 2014 | 6917 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 789 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1349 | 0.020 |
Why?
|
| Anemia | 1 | 2001 | 1510 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 336 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 6601 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2006 | 6427 | 0.020 |
Why?
|
| Life Style | 1 | 2003 | 3928 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3805 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2015 | 904 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2598 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 272 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9747 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2010 | 69 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 455 | 0.020 |
Why?
|
| California | 1 | 2014 | 1434 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 1258 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 592 | 0.020 |
Why?
|
| Calcium | 1 | 2003 | 5765 | 0.020 |
Why?
|
| Brachytherapy | 2 | 2010 | 1220 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 700 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 561 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1606 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 2859 | 0.020 |
Why?
|
| Mutation | 2 | 2016 | 30184 | 0.020 |
Why?
|
| Nomograms | 1 | 2010 | 235 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 109 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 101 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 178 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 4269 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2036 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 17062 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2008 | 313 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3605 | 0.020 |
Why?
|
| Threonine | 1 | 2007 | 272 | 0.020 |
Why?
|
| Histidine | 1 | 2007 | 301 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2014 | 2002 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3423 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2014 | 1063 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 546 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 453 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2008 | 15749 | 0.020 |
Why?
|
| Prevalence | 1 | 2002 | 15833 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1377 | 0.020 |
Why?
|
| American Heart Association | 1 | 2010 | 1047 | 0.010 |
Why?
|
| Estradiol Congeners | 1 | 2004 | 22 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1185 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2005 | 148 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3140 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2010 | 1884 | 0.010 |
Why?
|
| Palliative Care | 2 | 2014 | 3645 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2007 | 1984 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 2415 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20667 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 2004 | 111 | 0.010 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 2538 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 1259 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2013 | 1949 | 0.010 |
Why?
|
| Tyrosine | 1 | 2007 | 1427 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4520 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7835 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2010 | 1248 | 0.010 |
Why?
|
| Microfluidics | 1 | 2007 | 651 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2010 | 1187 | 0.010 |
Why?
|
| Finasteride | 1 | 2003 | 86 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2895 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 898 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3229 | 0.010 |
Why?
|
| Creatinine | 1 | 2007 | 1915 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3504 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3623 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3339 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4254 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4106 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 1883 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2586 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2007 | 22224 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3684 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 8293 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 4909 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1728 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 752 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 1494 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 8062 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 5445 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13261 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 7066 | 0.000 |
Why?
|
| Anticoagulants | 1 | 2004 | 4862 | 0.000 |
Why?
|
| Mice | 1 | 2015 | 81792 | 0.000 |
Why?
|
| Young Adult | 1 | 2014 | 59852 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 20120 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 18061 | 0.000 |
Why?
|